Biocon Ltd. continued its strong showing in the fourth quarter, buoyed by momentum in its biologics business and robust growth in its research services segment. The Indian firm also appears to have taken more definitive steps towards eventually unlocking value from the biologics business via a potential initial public offer (IPO), though it did not share specifics or timelines on such plans.
Biocon Biologics Reaches Landmark Sales Figure; IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
